Physicians
A better future for patients and families
From the beginning, Y-mAbs has focused on developing novel treatments for some of the most difficult and rare diseases in pediatric oncology. By working in partnership with healthcare providers, we can bring innovative antibody-based therapies to more patients and help improve outcomes for some of the most overlooked diseases in oncology.
Current clinical trials
Pediatric cancer has long been a challenge for the medical profession. Despite this, progress is made every day in labs and treatment centers around the world thanks to research and protocols made possible by the collaboration of clinicians and courageous families alike.
Expanded access for investigational medicines
Y-mAbs is a company built with a focus on patients with unmet medical needs in oncology. As such, we receive inquiries about making Y-mAbs’ investigational medicines available to patients with serious or life-threatening disease for whom enrollment in clinical trials is not an option and there are no beneficial therapies available.
Y-mAbs has established a process whereby certain patients may gain access to Y-mAbs investigational therapies on an “expanded access” or “compassionate use” basis provided certain criteria are met. This process is available only in certain countries and for limited periods.
Process
For more information about, or to be considered for expanded access/compassionate use, a patient’s treating physician must first make a request via email to [email protected]. Once Y-mAbs has received the information required for consideration an acknowledgement receipt of the request will typically be sent within five (5) business days. If you are a patient or inquiring on behalf of a patient interested in Y-mAbs’ expanded access/compassionate use, please talk to your doctor.
Evaluation criteria
All requests for compassionate use of investigational medicines are carefully considered, and decisions are thoughtfully made based on various factors, with the patient’s safety and wellbeing the top priority. Y-mAbs cannot guarantee that any specific request will be fulfilled and will evaluate each request based on but not limited to the following criteria:
- The patient has a serious or life-threatening disease and there are no beneficial treatment options available
- The potential benefits of the investigational medicine likely outweigh potential risks
- There is an adequate supply of the investigational medicine
- The patient is ineligible or cannot participate in clinical trials for the investigational medicine
- The treating physician can be fully informed on the safe and appropriate use of the investigational medicine
- Providing access to the investigational medicine does not interfere with patient enrollment or other aspects of the clinical trials necessary to support registration of the investigational medicine
- Other discretionary factors as Y-mAbs deems appropriate
Y-mAbs reserves the right to revise its expanded access/compassionate use policy in whole or in part at any time, without notice.